GGrantIndex
← Leaderboards

Allen D Everett

University Of Virginia Charlottesville

Google Scholar ↗PubMed ↗ORCID ↗
$14,760,201
Attributed
$21,289,780
Total exposure
13
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.5M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$21,289,780 · 13

By mechanism

R01$17,810,283 · 7
U54$990,905 · 1
RC1$924,643 · 1
T32$839,168 · 1
R21$562,781 · 2
R03$162,000 · 1

Top collaborators

Others in their field

Top investigators on “Child”

Research focus

ChildCohortProteinsResponseSamplingInnovationBaseValidationChildhoodDiagnosticAdultSerumPathway InteractionsPrognosticUniversitiesFutureImproved OutcomeNational Heart, Lung, And Blood InstituteCessation Of LifeNovel TherapeuticsMorbidity - Disease RateSeveritiesBrainEtiology

Grant awards (45)

Role of Cyclohexanone Toxicity in Mediating Congenital Cardiac Surgery Outcomes$688,618
R01 · FY2025 · HL · contact PI
Advanced therapeutic hypothermia efficacy network modeling in neonatal HIE$655,982
R01 · FY2025 · HD
Role of Cyclohexanone Toxicity in Mediating Congenital Cardiac Surgery Outcomes$745,123
R01 · FY2024 · HL · contact PI
Advanced therapeutic hypothermia efficacy network modeling in neonatal HIE$654,440
R01 · FY2024 · HD
Training for Clinician Scientists in Pediatric Critical Cardiopulmonary Disease$183,995
T32 · FY2024 · HL · contact PI
Role of Cyclohexanone Toxicity in Mediating Congenital Cardiac Surgery Outcomes$723,076
R01 · FY2023 · HL · contact PI
Advanced therapeutic hypothermia efficacy network modeling in neonatal HIE$666,663
R01 · FY2023 · HD
Role of IGF axis in pulmonary hypertension$660,065
R01 · FY2023 · HL · contact PI
Training for Clinician Scientists in Pediatric Critical Cardiopulmonary Disease$266,254
T32 · FY2023 · HL · contact PI
Role of Cyclohexanone Toxicity in Mediating Congenital Cardiac Surgery Outcomes$729,168
R01 · FY2022 · HL · contact PI
Advanced therapeutic hypothermia efficacy network modeling in neonatal HIE$715,813
R01 · FY2022 · HD
Role of IGF axis in pulmonary hypertension$687,903
R01 · FY2022 · HL · contact PI
Training for Clinician Scientists in Pediatric Critical Cardiopulmonary Disease$388,919
T32 · FY2022 · HL · contact PI
Role of IGF axis in pulmonary hypertension$704,278
R01 · FY2021 · HL · contact PI
Role of IGF axis in pulmonary hypertension$740,403
R01 · FY2020 · HL · contact PI
Clinical and mechanistic role of HDGF in pulmonary hypertension$588,248
R01 · FY2020 · HL · contact PI
Adult Biomarkers in Neonatal Brain Injury and Development$530,508
R01 · FY2020 · HD · contact PI
Clinical and mechanistic role of HDGF in pulmonary hypertension$675,012
R01 · FY2019 · HL · contact PI
Adult Biomarkers in Neonatal Brain Injury and Development$636,878
R01 · FY2019 · HD · contact PI
Role of IGF in pulmonary arterial hypertension severity and survival$135,749
R21 · FY2019 · HL · contact PI
Adult Biomarkers in Neonatal Brain Injury and Development$649,092
R01 · FY2018 · HD · contact PI
Clinical and mechanistic role of HDGF in pulmonary hypertension$638,631
R01 · FY2018 · HL · contact PI
Clinical and mechanistic role of HDGF in pulmonary hypertension$271,992
R01 · FY2018 · HL · contact PI
Clinical and mechanistic role of HDGF in pulmonary hypertension$695,821
R01 · FY2017 · HL · contact PI
Adult Biomarkers in Neonatal Brain Injury and Development$668,667
R01 · FY2017 · HD · contact PI
Adult Biomarkers in Neonatal Brain Injury and Development$656,559
R01 · FY2016 · HD · contact PI
Transistor and Circuit Designs for Real Time Brain Injury Biomarker Detection$199,392
R21 · FY2016 · EB
Transistor and Circuit Designs for Real Time Brain Injury Biomarker Detection$227,640
R21 · FY2015 · EB
GFAP Biomarker of Whole Body Cooling Outcome and Efficacy in the Neonate with HIE$424,723
R01 · FY2012 · HD · contact PI
Circulating biomarkers of IPAH.$81,000
R03 · FY2012 · HL · contact PI
Proteomics of silent cerebral infarction biomarker in Sickle Cell Disease$375,182
U54 · FY2011 · HL · contact PI
Circulating biomarkers of IPAH.$81,000
R03 · FY2011 · HL · contact PI
Quantifiable biomarkers of vasodilator therapeutic response in children with IPAH$463,441
RC1 · FY2010 · HL · contact PI
Hepatoma derived growth factor and vascular smooth muscle cell proliferation$369,000
R01 · FY2010 · HL · contact PI
Quantifiable biomarkers of vasodilator therapeutic response in children with IPAH$461,202
RC1 · FY2009 · HL · contact PI
Hepatoma derived growth factor and vascular smooth muscle cell proliferation$369,000
R01 · FY2009 · HL · contact PI
Proteomics of silent cerebral infarction biomarker in Sickle Cell Disease$243,891
U54 · FY2009 · HL · contact PI
Proteomics of silent cerebral infarction biomarker in Sickle Cell Disease$371,832
U54 · FY2008 · HL · contact PI
Hepatoma derived growth factor and vascular smooth muscle cell proliferation$369,000
R01 · FY2008 · HL · contact PI
Hepatoma derived growth factor and vascular smooth muscle cell proliferation$354,920
R01 · FY2007 · HL · contact PI
Hepatoma Derived Growth Factor &VSM Cell Proliferation$408,750
R01 · FY2005 · HL
Hepatoma Derived Growth Factor &VSM Cell Proliferation$408,750
R01 · FY2004 · HL
Hepatoma Derived Growth Factor &VSM Cell Proliferation$187,177
R01 · FY2003 · HL
Hepatoma Derived Growth Factor &VSM Cell Proliferation$182,823
R01 · FY2003 · HL
Hepatoma Derived Growth Factor &VSM Cell Proliferation$353,200
R01 · FY2002 · HL